Rituximab News and Research

RSS
Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
Ibrutinib-based therapy provides superior clinical outcomes in majority of CLL patients

Ibrutinib-based therapy provides superior clinical outcomes in majority of CLL patients

Study: Calcium signaling can help address drug resistance to non-Hodgkin lymphoma

Study: Calcium signaling can help address drug resistance to non-Hodgkin lymphoma

Tailored T-cells safe, may be effective in preventing and treating multiple viral infections

Tailored T-cells safe, may be effective in preventing and treating multiple viral infections

Drug regimen for lymphoma and RA more likely to put patients with pemphigus into remission

Drug regimen for lymphoma and RA more likely to put patients with pemphigus into remission

Juvenile immune arthritis – new treatments wanted

Juvenile immune arthritis – new treatments wanted

Tocilizumab more effective than rituximab in achieving low disease activity in RA patients

Tocilizumab more effective than rituximab in achieving low disease activity in RA patients

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

New research shows significant gaps in deployment of 'coverage with evidence development'

New research shows significant gaps in deployment of 'coverage with evidence development'

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

Study reveals investigational drug as effective treatment for relapsed marginal zone lymphoma

Study reveals investigational drug as effective treatment for relapsed marginal zone lymphoma

Researchers find cause, treatment for CVID lung disease using precision medicine

Researchers find cause, treatment for CVID lung disease using precision medicine

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

Scientists discover key aspect in the development of multiple sclerosis

Scientists discover key aspect in the development of multiple sclerosis

Researchers discover key aspect in pathogenesis of multiple sclerosis

Researchers discover key aspect in pathogenesis of multiple sclerosis

Study shows B cells could play reciprocal roles in pathogenesis of systemic sclerosis

Study shows B cells could play reciprocal roles in pathogenesis of systemic sclerosis